Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

There are two types: dry macular degeneration, which progresses slowly, and wet macular degeneration, which can lead to rapid vision loss due to abnormal blood vessel growth beneath the retina. While ...

For the past several years, the halls of the Las Vegas Convention Center have been lousy with AR/VR/XR smart glasses. While ...

A new eye drop therapy offers a non-invasive alternative for treating dry age-related macular degeneration. Massively ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced central ...

Age related macular degeneration (AMD) is the leading cause of vision loss in individuals over 65, characterized by abnormal ...

CU-06 is under development for the treatment of diabetic macular edema, wet macular degeneration, ulcerative colitis and colon cancer. It is administered through oral route. The drug candidate acts by ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema ...

ABBVRGX-314 is under clinical development by AbbVie and currently in Phase II for Diabetic Macular Edema. According to GlobalData, Phase II drugs for Diabetic Macular Edema have a 47% phase transition ...

Essex Bio-Technology ( (HK:1061) ) has provided an announcement.

Outlook Therapeutics ( (OTLK) ) has released its Q4 earnings. Here is a breakdown of the information Outlook Therapeutics presented to its ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced ...